This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells. Giving carboplatin before surgery may shrink tumors in patients with high-risk prostate cancer with BRCA1 and BRCA2 gene mutations.
Participant must have histologic diagnosis of prostate adenocarcinoma
cT3a - cT4x
Grade group 4 or 5 (Gleason sum 8-10)
PSA > 20 ng/mL prior to registration
Participant must not have evidence of distant metastatic disease by conventional imaging within 90 days prior to registration
NOTE: cN1 detected only by PSMA-PET is permitted if urologist deems sites of disease to be potentially completely resectable
Participant must not have received prior radiation therapy (RT) to the pelvic region
Participant must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of protocol treatment
SWOG Cancer Research Network
Lead sponsor
National Cancer Institute (NCI)
Collaborator